Why the study?
Does troglitazone reduce atherosclerotic lesion formation in male low density lipoprotein receptor-deficient mice?
Does troglitazone reduce atherosclerotic lesion formation in male low density lipoprotein receptor-deficient mice?
Troglitazone inhibits early atherosclerotic lesion formation in LDL receptor-deficient mice, likely through direct effects on the artery wall such as reducing macrophage accumulation.
No takes yet. Share an insight, caveat, or question.
May reduce early lesions in this murine model; leaves open human translation and clinical relevance.
Collins et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: